Palliser Capital UK Ltd Invests $2.05 Million in Becton, Dickinson and Company $BDX

Palliser Capital UK Ltd acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,533 shares of the medical instruments supplier’s stock, valued at approximately $2,048,000. Becton, Dickinson and Company comprises approximately 1.1% of Palliser Capital UK Ltd’s investment portfolio, making the stock its 14th biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Auto Owners Insurance Co increased its position in shares of Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after acquiring an additional 40,528,680 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $3,721,533,000. Wellington Management Group LLP boosted its position in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on BDX shares. Bank of America decreased their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Price Performance

BDX stock opened at $190.58 on Tuesday. The business has a 50 day moving average price of $162.48 and a 200 day moving average price of $160.73. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $52.51 billion, a price-to-earnings ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 11,704 shares of company stock valued at $1,963,618. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.